FDA approves weekly subcutaneous lecanemab for Alzheimer’s
AI Summary
The FDA has approved lecanemab, a weekly subcutaneous treatment for Alzheimer's disease. This marks a significant development in Alzheimer's therapeutic options.
Related Articles
Nigeria’s economy making progress despite reform pains, says Tinubu
Punch Nigeria —
Lee-Chin’s Portland Holdings targets Türkiye’s nuclear energy sector
Jamaica Observer —
Update On The Future Of This Manchester City Midfielder This Summer: What Should Maresca Do?
Yahoo Sports —
Thinking Machines Lab Drops Its First Model
Wired —
What Pa.’s getting from McCormick’s defense summit: $10 billion, thousands of jobs
Harrisburg Patriot-News —
Allegiant Air flights are now available on Expedia
The Points Guy —